Eight weeks of Curcuma longa L. supplementation improves disease activity and quality of life in Ulcerative Colitis patients: a pilot study / Suplementação de Curcuma longa L. por oito semanas melhora a atividade da doença e a qualidade de vida de pacientes com Colite Ulcerativa: um estudo piloto
Keywords:Ulcerative Colitis, Turmeric, Inflammation, Nutritional assessment, Quality of life.
This study evaluated the effects of Curcuma longa L, combined with Mesalamine on inflammation and quality of life in patients with Ulcerative Colitis (UC). A randomized, double-blind, pilot study was undertaken with nine patients, age ?18 years, who were exclusively using Mesalamine (3g/day). These patients were kept under observation in a university hospital for eight weeks. An experimental group (EG) (n=5) received three capsules daily, containing 500mg of dry extract of Curcuma longa L. and a control group (CG) (n=4), 500mg of microcrystalline cellulose. The groups were evaluated for the following, before and after the intervention: rectosigmoidoscopy, fecal calprotectin, body mass index (BMI), interleukin 10 (IL10), C-reactive protein (CRP), haemoglobin and haematocrit. A Short Form Health Survey (SF36) questionnaire was used to assess quality of life. When individually evaluated, EG patients showed histological improvement (Effect size: 0.706) in the rectosigmoidoscopy examination. 80% of them presented calprotectin values within the normal range. BMI analysis showed that 78% of the patients were overweight, but without difference between groups (p=0.456). The inflammation markers (IL10, CRP and calprotectin) as well as haemoglobin and haematocrit were not different in any of the groups. There was no difference in the SF-36 quality of life domains between groups, but the effect size was medium to large for the domains physical functioning, bodily pain, general health, social functioning, role-emotional and mental health. As conclusion the turmeric supplementation for eight weeks was able to reduce the Mayo score and improve the quality of life in patients with UC.
Pereira LCN, Finco JS. Estudo farmacoeconômico no tratamento de doença de crohn de moderada a grave. Brazilian Journal of Development. 2019; 5(8):11759-83.
Huoponen S, Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS One. 2015;10(12):e0145087. Review.
Suzuki Y, Iida M, Ito H, Nishino H, Ohmori T, Arai T, et al. 2.4 g mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: A randomized, noninferiority, multi-center trial. Inflamm Bowel Dis. 2017;23(5):822-32.
Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol 2015;13(8):1444-9.
Vilela CA, Artur PO. Secagem do açafrão (Curcuma longa L.) em diferentes cortes geométricos. Ciênc Tecnol Aliment, Campinas. 2008;28(2):387-94.
Singh S, Aggarwal BB. Activation of transcription factor NF-?B is suppressed by curcumin (diferulolylmethane) [Corrected]. J Biol Chem. 1995;270(42):24995-5000. Erratum in; J Biol Chem. 1995;270(50):30235.
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4912):1502-6.
Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci. 2005;50(11):2191-3.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2(4884):375-8. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2078989/pdf/brmedj03611-0009.pdf.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625-9.
World Health Organization (WHO). Obesity?: preventing and managing the global epidemic?: report of a WHO consultation (WHO Technical Report Series 894) [Internet]. WHO; 2000 [cited 2016 Apr 25]. Available online: https://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/
Lipschitz DA. Screening for nutritional status in the elderly. Prim Care 1994;21(1):55-67. Review.
Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, et al. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. Qual Life Res. 2018;27(20):273-90. Review.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Lawrence Erlbaum Associates; 1988. Available in: http://www.utstat.toronto.edu/~brunner/oldclass/378f16/readings/CohenPower.pdf.
Silva AF, Schieferdecker ME, Rocco CS, Amarante HM. Relação entre estado nutricional e atividade inflamatória em pacientes com doença inflamatória intestinal. ABCD Arq Bras Cir Dig. 2010;23(3):154-8.
Back IR, Marcon SS, Gaino NM, Vulcano DS, Dorna MS, Sassaki LY. Body composition in patients with crohn’s disease and ulcerative colitis. Arq Gastroenterol. 2017;54(2):109-14.
McCann MJ, Johnston S, Reilly K, Men X, Burgess EJ, Perry NB, et al. The effect of turmeric (Curcuma longa) extract on the functionality of the solute carrier protein 22 A4 (SLC22A4) and interleukin-10 (IL-10) variants associated with inflammatory bowel disease. Nutrients. 2014;6(10):4178-90.
McColl E, Han SW, Barton JR, Welfare MR. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res. 2004;13(4):805-11.